Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number

##

Overview

Projects 727
Countries 140
Faculty 431
Health Topics 137

Filter from the selections below

Clear All Filters

Developing Immunotherapy Approaches to Target Surface Proteins on Virally Infected Cancer Cells

Many EBV-associated cancers express virally-encoded transmembrane proteins. Two such proteins Latent Membrane Protein1 (LMP1) and Latent Membrane Protein 2 (LMP2) that play roles in oncogenesis. Both are multi-spanning transmembrane proteins, with a small extracellular region that is exposed on the surface of the infected cell.  Our hypothesis is that the exposed extracellular regions of LMP1 and LMP2 could be targeted by cytotoxic T cells expressing chimeric antigen receptors (CARs). However, the development of CAR based therapies to target LMP-expressing malignancies are currently hampered by a lack of antibodies that recognize the extracellular domains of these proteins. Using a humanized mouse model, we are working to isolate human antibodies that specifically recognize the extracellular domains of membrane-anchored LMP1 and LMP2, and to convert these antibodies into chimeric antigen receptors that can be used to direct potent T-cell-mediated killing to EBV+ cancer cells.